Neurogene Inc. (NGNE) stock
NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
$23.14+0.04 (+0.17%)
Close on Nov 18, 2026Market cap $463.06MP/E –Yield –
Neurogene revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Neurogene's revenue for the twelve months ending Dec 31, 2025 was $0, down 100.0% year over year. For fiscal 2025 it was $0, down 100.0% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | -100.0% |
| FY2024 | Dec 31, 2024 | $925.00K | – |
| FY2023 | Dec 31, 2023 | $0 | -100.0% |
| FY2018 | Dec 31, 2018 | $25.00M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $0 | – |
| Q3 FY2025 | Sep 30, 2025 | $0 | -100.0% |
| Q2 FY2025 | Jun 30, 2025 | $0 | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
| Q3 FY2024 | Sep 30, 2024 | $0 | – |
| Q2 FY2024 | Jun 30, 2024 | $925.00K | – |
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
| Q3 FY2023 | Sep 30, 2023 | $0 | -100.0% |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
| Q4 FY2018 | Dec 31, 2018 | $0 | – |
| Q3 FY2018 | Sep 30, 2018 | $0 | – |
| Q2 FY2018 | Jun 30, 2018 | $25.00M | – |
See a number that looks wrong?